Hepatocytes RNA silencing guide

Hepatocytes present unique biological barriers that cause conventional transfection to fail or create experimental artifacts invalidating drug metabolism and disease modeling studies:

Lipofection efficiency in hepatocytes

Lipofection depends on the lipoplex being taken up and released from the endosome, so how much cargo reaches the cytosol depends on the reagent, and it is inefficient in primary human hepatocytes. These cells are post-mitotic and metabolically active. Even HepG2 and Huh7 cell lines, which are immortalized and typically easier to transfect, take up a fraction of the cargo with standard lipofection protocols.

De-differentiation, the culture and the delivery

The functions a hepatocyte is used for do not decay together, and the largest term is the culture rather than the delivery. In primary human hepatocytes with no transfection of any kind, cytochrome P450 mRNA fell 70-80% within four hours of seeding, measured against the same cells in suspension, with slow or negligible recovery for every enzyme but CYP2C19, while albumin and urea secretion fell far more slowly, over weeks, and the cells kept their differentiated phenotype through day 21. So a CYP450 activity read a day or two after plating is dominated by that baseline, and attributing it to a reagent requires a culture-only arm run beside the experiment. What a reagent adds on top of the baseline, including anything it does to the hepatocyte transcription factors HNF4α and HNF1α, is what the non-targeting control and the reagent-only arm measure against untreated cells.

Culture lifespan, function by function

Primary human hepatocytes in standard 2D culture hold their functions for different lengths of time, and the experimental window is the shortest of them, not an average: cytochrome P450 expression falls in the first hours after seeding and recovers slowly or not at all for every enzyme but CYP2C19, while albumin and urea secretion fall far more slowly, over weeks. This narrow experimental window is further constrained by transfection optimization requirements. Conventional transfection methods require 2-4 days for delivery and 3-5 days for protein knockdown validation, which consumes much of the viable culture period before functional assays can begin. Extended cultures (>14 days) show progressive loss of CYP450 expression, reduced metabolic competence, and altered gene expression profiles, limiting longitudinal studies.

Electroporation-induced toxicity and functional loss

Hepatocytes are sensitive to electroporation. The high voltage pulses transfection requires cost viability in primary hepatocytes, and surviving cells often show profoundly disrupted morphology and function. Electroporation can damage bile canaliculi (the apical membrane domains where hepatocytes secrete bile), disrupt tight junctions (essential for hepatocyte polarity), cause mitochondrial dysfunction (hepatocytes are rich in mitochondria for metabolic activity), and trigger oxidative stress responses. Functional assays may become unreliable: CYP450 activity reduced, albumin secretion diminished, and drug transporter expression altered.

Lipid droplets and lipid-based reagents

Hepatocytes naturally contain lipid droplets for triglyceride storage and lipoprotein synthesis. In NAFLD/NASH disease models (induced by fatty acid loading: oleate/palmitate treatment), lipid droplets occupy 30-60% of cellular volume. A cationic lipid reagent adds further lipid to a cell already loaded with it; a delivery step that brings no cationic lipid adds none.

Sandwich culture and 3D spheroids, and what a reagent has to cross

The hepatocyte culture systems that best preserve hepatocyte function are the hardest for a transfection reagent to cross. Collagen sandwich culture (hepatocytes sandwiched between two collagen layers) maintains hepatocyte polarity, bile canaliculi formation, and extended function (21-28 days), but the collagen overlay stands between a lipofection reagent and the cells. Similarly, 3D hepatocyte spheroids (multicellular aggregates) recapitulate in vivo tissue architecture and improve CYP450 expression, but how far a transfection reagent penetrates depends on the reagent and on the size of the aggregate, and the core can be left untreated. These culture systems are gold standards for drug metabolism studies, so what a delivery step has to cross is part of choosing one.

Method comparison

Gene silencing in hepatocytes with no transfection reagent

Hepatocyte function during knockdown

Key benefits

• Maintains hepatocyte viability
  Preserves cell health for functional assays requiring viable hepatocytes: CYP450 activity (luminescent assay), albumin secretion (ELISA), urea synthesis, drug transporter function.
• No reagent in a CYP450 readout
  Cytochrome P450 collapses in the first hours of culture with no transfection at all, so a CYP450 result carries that baseline whatever is added to the medium. AUMsilence sdASO adds no cationic lipid, so the reagent is not one of the terms; read the isoform activity by luminescent assay against the non-targeting control, and that control against untreated cells.
• Enables authentic NAFLD/NASH studies
  Knockdown FASN, SCD1, SREBP1C, PNPLA3 in oleate/palmitate-loaded hepatocytes to study lipid metabolism pathways. Lipid droplets do not interfere; critical for steatosis research.
• Compatible with primary human hepatocytes
  Typically 70-95% knockdown in cryopreserved primary human hepatocytes, the gold standard for drug metabolism studies.
• Rapid timeline for drug metabolism studies
  No viral vector cloning, no transfection optimization. Test CYP450 gene function in 3-5 days (plate hepatocytes, add ASO, validate knockdown, perform CYP450 activity assays).
• Extended culture compatibility
  Works in 7-14 day standard cultures, 21-28 day sandwich cultures, and 4-6 week spheroid cultures. A primary hepatocyte is post-mitotic, so the oligonucleotide is not diluted by division and a further dose may not be needed for 10 to 14 days.

Cell types and applications

• Primary human hepatocytes (fresh or cryopreserved)
• Drug metabolism and pharmacokinetics (DMPK) studies
• CYP450 enzyme function and drug-drug interactions
• Drug-induced liver injury (DILI) mechanisms
• NAFLD/NASH disease modeling and target identification
• Viral hepatitis research (HBV, HCV host factors)
• Metabolic liver disease studies (Wilson's, hemochromatosis, glycogen storage)
• Drug transporter function (OATP, MDR1, MRP2)
• Hepatocyte cell lines (HepG2, Huh7, HepaRG)
• Collagen sandwich culture systems
• 3D hepatocyte spheroids and organoids
• Co-culture models (hepatocytes + stellate cells + Kupffer cells)
• Pharmaceutical drug development and toxicology

• Learn more about AUMsilence™ sdASO™

Alternative products

AUMantagomir™ sdASO™

• Learn more about AUMantagomir™ sdASO™

AUMlnc™ sdASO™

• Learn more about AUMlnc™ sdASO™

Optimized protocols for primary human hepatocytes, hepatocyte cell lines, and 3D culture systems. No transfection reagents required.

Quick start protocol (all hepatocyte types)

1. 01Seed hepatocytes on collagen-coated plates in hepatocyte maintenance medium
2. 02Add AUMsilence™ sdASO™ directly to culture medium at 10 μM (no transfection reagent)
3. 03Incubate 48-72 hours at 37°C, 5% CO₂
4. 04Validate knockdown by qRT-PCR (mRNA, 48h after treatment) and Western blot (protein, 72h after treatment)
5. 05Perform functional assays: CYP450 activity (luminescent assay), albumin secretion (ELISA), urea synthesis (colorimetric assay)

Cell-type-specific protocols

Primary human hepatocytes (collagen sandwich culture)

1. 01

   Step 1: Source and thaw primary hepatocytes

   Obtain cryopreserved primary human hepatocytes from commercial vendors. Thaw vials according to manufacturer protocol: rapid thaw in 37°C water bath, dilute slowly with thawing medium, centrifuge gently (50-100g, 5 min). Resuspend in hepatocyte plating medium.
   Materials: Cryopreserved primary human hepatocytes, thawing medium (supplier-provided), plating medium (Williams' E + 5% FBS + ITS supplement + dexamethasone 0.1 μM)
   Note: Handle gently: primary hepatocytes are fragile. Avoid vortexing or harsh pipetting. Above 80% post-thaw is a lot-acceptance threshold a buyer applies when selecting a research-grade lot, not the average a batch delivers: across 144 thawing events on 81 clinical-grade batches the measured mean was 61.0%, range 42-90%. Count the viable cells you plate rather than assuming the threshold.
   Day 0
2. 02

   Step 2: Plate on collagen type I

   Plate hepatocytes at 0.5-1.0 × 10⁵ cells/cm² on collagen Type I-coated plates (rat tail collagen, 50 μg/mL coating, overnight at 4°C). Use Williams' E medium + 5% FBS + insulin-transferrin-selenium (ITS) + dexamethasone (0.1 μM) + penicillin/streptomycin. Incubate 4-6 hours to allow attachment.
   Materials: Collagen Type I-coated plates, Williams' E medium, FBS, ITS, dexamethasone
   Note: Cell density critical: too high (>1.5 × 10⁵/cm²) causes hypoxia, too low (<3 × 10⁴/cm²) reduces cell-cell contact and function.
   Day 0
3. 03

   Step 3: Overlay with collagen (sandwich configuration)

   After 4-6h attachment, gently aspirate medium and overlay with ice-cold collagen Type I solution (0.25 mg/mL in culture medium, neutralized to pH 7.4 with NaOH). Incubate 30-60 min at 37°C to allow collagen polymerization. Add fresh maintenance medium on top of collagen overlay.
   Materials: Collagen Type I (0.25 mg/mL), 1 N NaOH for pH adjustment, maintenance medium (serum-free Williams' E + ITS + dexamethasone)
   Note: Collagen overlay maintains hepatocyte polarity and bile canaliculi for 14-28 days. Extend functional lifespan 2-3× vs. standard culture.
   Day 0 (evening) or Day 1 (morning)
4. 04

   Step 4: Culture equilibration

   Culture hepatocytes in serum-free maintenance medium (Williams' E + ITS + dexamethasone 0.1 μM) for 24-48h to allow stabilization of hepatocyte-specific functions. Perform media changes every 24h. Verify hepatocyte morphology: polygonal shape, clear cytoplasm, visible bile canaliculi between cells.
   Materials: Serum-free hepatocyte maintenance medium
   Note: CYP450 enzyme expression stabilizes by Day 2-3. Optimal for drug metabolism studies from Day 3 onward.
   Days 1-2
5. 05

   Step 5: AUMsilence sdASO treatment

   At Day 2-3 (stabilized hepatocytes), add AUMsilence sdASO directly to culture medium at 10 μM final concentration. For 1 mL medium per well (24-well plate), add 10 μL of 1 mM AUMsilence sdASO stock. Mix gently by rocking plate. No media change required. Cellular uptake begins within 4-6 hours of addition.
   Materials: AUMsilence sdASO (1 mM stock in nuclease-free water)
   Note: Compatible with collagen sandwich culture: ASO can penetrate collagen overlay to reach hepatocytes. No interference with hepatocyte polarity.
   Day 2-3
6. 06

   Step 6: Validation and functional assays

   At 48h post-treatment: extract RNA for qRT-PCR, typically 70-95% knockdown. At 72h: harvest cells for Western blot for protein reduction, or perform functional assays: (1) CYP450 activity: luminescent assays for CYP3A4, CYP2D6, CYP1A2 (luminescent substrate conversion), (2) Albumin secretion: collect medium, measure by ELISA, (3) Urea synthesis: incubate with 2 mM NH₄Cl for 2h, measure urea in medium by colorimetric assay.
   Materials: RNA extraction kit, qPCR reagents, Western blot reagents, luminescent CYP450 activity assay kits, albumin ELISA, urea assay kit
   Note: AUMsilence sdASO-treated hepatocytes maintain normal CYP450 activity, albumin secretion, and urea synthesis unless targeting those pathways specifically.
   Days 4-6

HepG2 cells (human hepatocellular carcinoma line)

1. 01

   Step 1: HepG2 culture

   Culture HepG2 cells in DMEM + 10% FBS + 1% Pen/Strep. Maintain cells in log-phase growth, splitting 1:4 every 3-4 days when reaching 80-90% confluency. HepG2 cells are adherent and proliferate continuously.
   Materials: DMEM high glucose, FBS, antibiotics
   Note: HepG2 cells retain some hepatocyte functions (albumin secretion, drug transporters) but have reduced CYP450 expression compared to primary hepatocytes.
   Ongoing maintenance
2. 02

   Step 2: Seeding for experiments

   Seed HepG2 at 5 × 10⁴ cells/cm² in 24-well plates (or appropriate format). Culture 24-48h until 60-70% confluent. Do not allow to reach full confluency (reduces metabolic activity).
   Materials: Standard cell culture materials
   Note: Sub-confluent HepG2 cells have higher metabolic activity and better recapitulate hepatocyte functions.
   Day -1 to 0
3. 03

   Step 3: AUMsilence sdASO treatment

   Add AUMsilence sdASO at 10 μM to HepG2 cultures; it is taken up by endocytosis. Useful for screening ASO sequences before moving to primary hepatocytes.
   Materials: AUMsilence sdASO
   Note: HepG2 cells are easier to culture and less expensive than primary hepatocytes. Use for initial optimization, then validate in primary cells.
   Day 0
4. 04

   Step 4: Validation

   Validate knockdown at 48h after treatment (qRT-PCR) and 72h (Western blot). HepG2 cells useful for studying lipid metabolism (FASN, SCD1, SREBP1C), drug transporters (ABCB1, ABCC2), and inflammatory responses (IL-6, TNF-α production). Limited CYP450 expression; less suitable for drug metabolism studies.
   Materials: Standard validation reagents
   Note: Always confirm HepG2 findings in primary hepatocytes for publication. HepG2 is a cancer cell line; gene expression profiles differ from normal hepatocytes.
   Days 2-3

Huh7 cells (more differentiated hepatoma line)

1. 01

   Step 1: Huh7 culture

   Culture Huh7 cells in DMEM + 10% FBS. Huh7 cells are more differentiated than HepG2 and permissive to HCV infection (useful for viral hepatitis research). Morphology: larger, more hepatocyte-like than HepG2.
   Materials: DMEM, FBS
   Note: Huh7 cells express higher CYP450 levels than HepG2 (though still lower than primary hepatocytes). Better model for drug metabolism screening.
   Ongoing maintenance
2. 02

   Step 2: AUMsilence sdASO treatment

   Seed Huh7 at 5 × 10⁴/cm², culture 24h, then treat with AUMsilence sdASO at 10 μM. Huh7 shows similar knockdown efficiency to HepG2. Particularly useful for viral hepatitis studies (knockdown host factors for HCV replication).
   Materials: AUMsilence sdASO
   Note: For HCV studies: transduce Huh7 with HCV replicon or infect with HCVcc, then add AUMsilence sdASO to knock down host factors (CD81, claudin-1, scavenger receptor B1).
   Day 0
3. 03

   Step 3: Applications

   Huh7 applications: (1) Viral hepatitis research (HCV replication), (2) Drug metabolism studies (CYP450 induction by rifampicin, phenobarbital), (3) Lipid metabolism (NAFLD modeling with oleate/palmitate), (4) Inflammasome activation (NLRP3 in NASH).
   Materials: Application-specific reagents
   Note: Huh7 more physiologically relevant than HepG2 for some applications but still inferior to primary hepatocytes.
   Days 2-5

Primary hepatocytes with NAFLD/NASH modeling

1. 01

   Step 1: Establish primary hepatocyte culture

   Plate primary human hepatocytes in collagen sandwich culture as described above. Allow 48h stabilization in maintenance medium.
   Materials: Primary hepatocytes, collagen sandwich culture
   Note: Use fresh hepatocytes, or a cryopreserved lot selected on its post-thaw viability, for NAFLD modeling; above 80% is the acceptance threshold rather than the average a batch gives.
   Days 0-2
2. 02

   Step 2: Lipid loading (NAFLD induction)

   At Day 2, switch to NAFLD-inducing medium: Williams' E + ITS + fatty acid cocktail (oleate 0.4 mM + palmitate 0.2 mM, complexed to BSA at 2:1 fatty acid:BSA molar ratio). Incubate 24-48h. Hepatocytes accumulate lipid droplets (steatosis phenotype).
   Materials: Oleic acid, palmitic acid, fatty acid-free BSA, Williams' E medium
   Note: Oleate:palmitate 2:1 ratio recapitulates physiological fatty acid composition. Higher palmitate causes lipotoxicity and apoptosis (NASH model).
   Days 2-4
3. 03

   Step 3: AUMsilence sdASO treatment in NAFLD model

   At 24h post-lipid loading (established steatosis), add AUMsilence sdASO at 10 μM to knock down lipid metabolism targets: FASN (fatty acid synthase), SCD1 (stearoyl-CoA desaturase-1), SREBP1C (master lipogenic transcription factor), PNPLA3 (NAFLD susceptibility gene), APOB (apolipoprotein B, lipoprotein assembly). Continue lipid loading throughout ASO treatment.
   Materials: AUMsilence sdASO targeting lipid metabolism genes
   Note: Lipid droplets do NOT interfere with AUMsilence sdASO delivery by endocytosis (unlike lipofection). This is critical advantage for NAFLD research.
   Day 3
4. 04

   Step 4: NAFLD/NASH phenotype assessment

   At 72h post-ASO treatment: (1) Lipid accumulation: Oil Red O staining (neutral lipids), Nile Red flow cytometry (quantitative), triglyceride content (enzymatic assay), (2) Inflammation: measure IL-6, TNF-α, IL-1β secretion by ELISA, (3) Oxidative stress: ROS measurement (DCF-DA), lipid peroxidation (TBARS assay), (4) Fibrosis markers: qRT-PCR for COL1A1, TGFB1, ACTA2 (α-SMA). Test whether target knockdown reduces steatosis, inflammation, or fibrosis markers.
   Materials: Oil Red O, Nile Red, triglyceride assay, ELISA kits, ROS probes
   Note: FASN or SCD1 knockdown reduces lipid accumulation. SREBP1C knockdown prevents lipogenesis. PNPLA3 knockdown modulates lipid droplet dynamics.
   Days 5-7

3D hepatocyte spheroids

1. 01

   Step 1: Spheroid formation

   Use ultra-low attachment 96-well plates or hanging drop method. Seed 1,500-3,000 primary hepatocytes per spheroid in Williams' E + 2% FBS + ITS. Hepatocytes self-assemble into spheroids within 24-48h. Optionally co-culture with non-parenchymal cells (stellate cells, Kupffer cells, endothelial cells) at 10:1 ratio for enhanced functionality.
   Materials: Ultra-low attachment plates, Williams' E medium, ITS
   Note: Spheroids maintain CYP450 expression for 4-6 weeks (vs. 7-14 days in 2D culture). Used for chronic drug exposure studies.
   Days 0-2
2. 02

   Step 2: Spheroid maturation

   Culture spheroids 5-7 days for full maturation. Spheroids develop organized architecture: hepatocytes in core, non-parenchymal cells (if included) in outer layers. CYP450 expression stabilizes by Day 5. Monitor spheroid diameter (200-400 μm optimal; >500 μm develops hypoxic core).
   Materials: Maintenance medium changes every 2-3 days
   Note: Smaller spheroids (<150 μm) lack sufficient cell-cell contacts. Larger spheroids (>500 μm) develop necrotic cores.
   Days 2-7
3. 03

   Step 3: AUMsilence sdASO treatment in spheroids

   Add AUMsilence sdASO at 10 μM directly to spheroid culture medium. Endocytosis allows ASO penetration throughout spheroid (unlike lipofection which only transfects surface cells). Incubate 48-72h.
   Materials: AUMsilence sdASO
   Note: A higher concentration within 5-20 μM may improve penetration in larger spheroids. ASO reaches core cells within 12-24h of addition by diffusion and cellular uptake.
   Day 7
4. 04

   Step 4: Validation and functional assays

   Harvest spheroids at 48-72h post-treatment. (1) qRT-PCR: lyse spheroids in phenol-guanidinium RNA extraction reagent, extract total RNA, (2) Whole spheroid imaging: fix, embed in OCT, cryosection, immunofluorescence for target protein (verify knockdown throughout spheroid depth), (3) CYP450 activity: incubate spheroids with luminescent assay substrates, measure luminescence in medium, (4) Albumin secretion: collect conditioned medium, ELISA.
   Materials: RNA extraction reagents, cryosectioning equipment, luminescent CYP450 assay kits, albumin ELISA
   Note: Spheroids can be cultured 4-6 weeks post-ASO treatment for chronic drug exposure studies. A hepatocyte in a spheroid divides little, so a further dose of AUMsilence sdASO may not be needed for 10 to 14 days.
   Days 9-11

Essential controls for hepatocyte experiments

• Untreated hepatocytes: Baseline for hepatocyte-specific functions (CYP450, albumin, urea synthesis)
  Culture identically but without ASO addition. Critical for confirming no de-differentiation from ASO treatment.
• Non-targeting control ASO: Control for non-specific ASO effects on hepatocyte biology
  Use AUM non-targeting control ASO at 10 μM (match experimental ASO concentration and timing). Verifies that functional changes are target-specific.
• Hepatocyte function markers: Validate hepatocyte differentiation state is maintained
  Measure at baseline and post-treatment: (1) CYP450 enzyme activity (expect no change with non-targeting ASO), (2) Albumin secretion (stable), (3) Urea synthesis (stable). Decreased function indicates de-differentiation.
• Positive control for de-differentiation: Compare lipofection with AUMsilence sdASO in the same experiment
  Optional: treat hepatocytes with standard lipofection reagent, measure CYP450 activity at 48h. Expect a reduction (de-differentiation). Compare with AUMsilence sdASO-treated hepatocytes cultured in parallel.

Optimization strategies for hepatocyte applications

• ASO concentration
  Recommendation: The recommended working range is 5-20 μM, with a starting concentration of 10 μM.
  Rationale: Hepatocytes are large cells (20-30 μm diameter) with high cytoplasmic volume, and a spheroid adds a diffusion path, so both may need the upper part of that range.
• Incubation time
  Recommendation: 48h for mRNA validation, 72h for protein validation and functional assays.
  Rationale: Hepatocyte protein half-lives vary: CYP450 enzymes (24-72h), albumin (20 days, measure secretion not intracellular), metabolic enzymes (12-72h). Plan validation timing based on target protein stability.
• Culture format
  Recommendation: Standard 2D for short-term studies (3-7 days), collagen sandwich for extended cultures (14-28 days), 3D spheroids for chronic drug exposure (4-6 weeks).
  Rationale: Culture format determines functional lifespan. AUMsilence sdASO compatible with all formats. Choose based on experimental timeline and required hepatocyte functions.
• NAFLD modeling timing
  Recommendation: Establish steatosis first (24-48h lipid loading), then add AUMsilence sdASO. Continue lipid loading during ASO treatment.
  Rationale: Pre-established steatosis recapitulates NAFLD state. Adding ASO during lipid loading tests prevention; adding ASO to established steatosis tests reversal/treatment paradigm.
• Primary hepatocyte donor variability
  Recommendation: Use hepatocytes from at least 3 different donors for statistical power. Match donors by demographics if possible (age, sex, BMI).
  Rationale: Donor-to-donor variability in CYP450 expression (genetic polymorphisms), drug metabolism rates, and lipid accumulation susceptibility. Multiple donors ensure findings are not donor-specific.

Troubleshooting

Low knockdown efficiency (<50% in primary hepatocytes)

• Verify hepatocyte function markers: measure albumin secretion, urea synthesis, CYP450 activity. If reduced, hepatocytes are de-differentiating; use fresher cells or optimize culture conditions
• Increase AUMsilence sdASO within 5-20 μM
• Test positive control (GAPDH or ACTB knockdown) to verify ASO activity
• Switch to collagen sandwich culture for better hepatocyte stability
• Use hepatocytes within 5-7 days of plating (before de-differentiation)

Hepatocyte de-differentiation (loss of CYP450, albumin)

• Use collagen sandwich culture to extend functional lifespan to 21-28 days
• Verify medium composition: Williams' E + ITS + dexamethasone 0.1 μM required
• Check plating density: optimal 0.5-1.0 × 10⁵/cm²
• Include non-targeting control ASO; if it also shows de-differentiation, problem is culture conditions not ASO
• Consider switching to 3D spheroids for extended studies

Lipid droplet accumulation interfering with readouts

• Reduce fatty acid concentration: use 0.4 mM oleate + 0.2 mM palmitate (2:1 ratio). Higher concentrations cause lipotoxicity.
• For imaging: use far-red fluorophores to avoid lipid droplet autofluorescence (green-yellow range)
• Viability check: stain with propidium iodide or LDH release assay. If viability <70%, reduce palmitate (more lipotoxic than oleate)
• For Oil Red O staining: fix cells thoroughly (4% formaldehyde, 30 min) to prevent lipid droplet loss during staining

High variability between hepatocyte donors

• Use n≥3 donors for statistical power
• Match donors by key demographics: age (±10 years), sex, BMI (±5)
• Request donor CYP450 genotype information from vendor if available
• Normalize functional assays to protein content or cell number
• Consider using hepatocyte cell lines (HepG2, Huh7) for initial screening to reduce variability, then validate in primary cells

CYP450 activity not reduced despite mRNA knockdown

• Extend protein validation to 96-120h (CYP450 proteins are very stable)
• Verify knockdown of specific CYP450 isoform by Western blot with isoform-specific antibody
• Test substrate specific to target CYP450 (e.g., midazolam for CYP3A4, bufuralol for CYP2D6) to avoid cross-reactivity
• Measure CYP450 protein levels by Western blot in addition to activity assay
• Consider dual knockdown if multiple CYP450 isoforms metabolize the substrate

3D spheroid core not responding to ASO

• Use smaller spheroids (200-400 μm diameter): seed fewer cells (1,000-2,000/spheroid instead of 3,000)
• Increase AUMsilence sdASO within 5-20 μM for better penetration
• Treat spheroids earlier (Day 3-5) before hypoxic core develops
• Validate spheroid viability by viability/cytotoxicity dual staining (calcein AM/ethidium homodimer) before ASO treatment
• Section spheroids and perform immunofluorescence to verify ASO penetration depth

Quantitative RT-PCR (qRT-PCR)

Western blot

CYP450 activity assays (luminescent)

Albumin secretion ELISA

Urea synthesis assay

Oil Red O staining (lipid accumulation)

Immunofluorescence (hepatocyte markers)

Drug transporter function (fluorescent substrates)

Critical controls for hepatocyte validation

• Untreated hepatocytes
  Purpose: Baseline for all measurements (CYP450 activity, albumin secretion, urea synthesis)
  Culture identically to experimental group but without ASO addition. Essential for verifying no de-differentiation during culture period. Measure hepatocyte function markers at same timepoints.
• Non-targeting control ASO
  Purpose: Control for non-specific ASO effects on hepatocyte differentiation and function
  Use AUM non-targeting control ASO at 10 μM (match experimental ASO concentration and timing). Critical for hepatocytes: shows whether any de-differentiation is from culture conditions or from ASO treatment. Measure CYP450 activity, albumin secretion, urea synthesis; should match untreated cells.
• Positive control for CYP450 activity
  Purpose: Validate assay sensitivity and hepatocyte metabolic competence
  Treat hepatocytes with known CYP450 inducers or inhibitors: rifampicin (CYP3A4 inducer, 25 μM, 48h, expect 2-5× activity increase), ketoconazole (CYP3A4 inhibitor, 1 μM, expect >80% inhibition), 3-methylcholanthrene (CYP1A2 inducer). Validates that hepatocytes are metabolically competent and assays are working.
• De-differentiation marker panel
  Purpose: Verify hepatocyte differentiation state is maintained throughout experiment
  Measure at baseline (Day 0), Day 3, and endpoint: (1) qRT-PCR: ALB, TTR, HNF4A, HNF1A, CYP3A4, CYP2D6 (should remain stable), (2) Albumin secretion ELISA (stable), (3) Urea synthesis (stable), (4) Immunofluorescence: HNF4α nuclear localization (maintained). If any markers decline >30% in non-targeting ASO group, hepatocytes are de-differentiating (optimize culture conditions).
• Donor-matched hepatocytes (for primary cells)
  Purpose: Control for donor-to-donor variability in CYP450 expression and drug metabolism
  Use hepatocytes from minimum 3 different donors. Perform ASO treatment and validation in parallel for all donors. Calculate knockdown efficiency and functional impact per donor, then average. Accounts for genetic polymorphisms (CYP2D6 *1/*1 vs. *1/*2 vs. *2/*2 poor metabolizers), age, sex, BMI differences. Report donor demographics in publications.
• Lipofection comparison (demonstrates de-differentiation)
  Purpose: Optional. Compare AUMsilence sdASO with a conventional transfection method in the same experiment
  Treat primary hepatocytes with standard cationic lipid-based transfection reagent (with or without cargo). Measure at 24h, 48h, 72h: (1) CYP450 activity (expect a reduction from de-differentiation), (2) Albumin secretion (reduced), (3) Urea synthesis (reduced), (4) qRT-PCR for HNF4A, CYP3A4 (downregulated). Compare with AUMsilence sdASO-treated hepatocytes cultured in parallel.
• Time-course validation
  Purpose: Identify the optimal timing for protein knockdown and functional assays
  Harvest samples at 24h, 48h, 72h, 96h post-ASO treatment. Measure at each: (1) mRNA by qRT-PCR, (2) protein by Western blot, (3) a functional readout (CYP450 activity, lipid accumulation). Identifies optimal timepoint for each assay. Short-lived proteins (TNF-α, cytokines) respond faster; long-lived proteins (CYP450s, albumin) require longer.

Best practices

• Use biological triplicates (n=3 independent experiments) with different donor hepatocyte preparations for primary cells
• Validate knockdown at both mRNA (qRT-PCR, 48h after treatment) and protein (Western blot, 72h) levels
• Include hepatocyte function markers (CYP450 activity, albumin secretion, urea synthesis) in all experiments to verify no de-differentiation
• For NAFLD studies, validate steatosis by multiple methods: Oil Red O, Nile Red flow cytometry, and biochemical triglyceride assay
• For CYP450 studies, use luminescent activity assays (more sensitive than HPLC substrate depletion) and measure multiple isoforms to confirm specificity
• Report donor demographics for primary hepatocytes (age, sex, BMI, ethnicity, genotype if available)
• Use sandwich culture or 3D spheroids for drug transporter studies (requires hepatocyte polarity)
• Measure hepatocyte viability (Trypan blue, LDH release, viability/cytotoxicity dual staining) at all timepoints
• Use appropriate statistical tests (t-test, ANOVA) with p<0.05 threshold; for donor variability, use paired or mixed-model analysis
• For publication, validate key findings from cell lines (HepG2, Huh7) in primary human hepatocytes